Core Insights - AI is expected to significantly reduce the time required for new drug development from years to months, according to Demis Hassabis, CEO of DeepMind [1] - Despite advancements in AI-driven drug development, no AI-designed drugs have yet successfully completed clinical trials [1] - Isomorphic Labs, a subsidiary of DeepMind, is focused on commercializing AI systems like AlphaFold to predict protein behavior and is currently working on treatments for cancer and immune system diseases [2] Group 1 - Isomorphic Labs aims to transform many cancers into treatable chronic diseases through AI drug development [2] - The company has established partnerships with pharmaceutical giants Eli Lilly and Novartis, expanding their collaboration from three to six drug targets [2] - Demis Hassabis indicated that Isomorphic Labs has the potential to become a company valued over $100 billion [3] Group 2 - As of early this year, clinical trials for AI-designed drugs were expected to begin by the end of the year, but this has not yet occurred [3] - Initial validation points for drug development have been demonstrated, indicating progress towards clinical trials [3] - Isomorphic Labs recently secured $600 million in funding led by Thrive Capital [3]
制药业巨震前夜？谷歌(GOOGL.US)旗下DeepMind之父宣称：AI新药研发将“数月”颠覆“数年“
Zhi Tong Cai Jing·2025-09-12 06:59